Identification of NRAS Isoform 2 Overexpression As a Mechanism Facilitating BRAF Inhibitor Resistance in Malignant Melanoma

Significance This study indicates that one of the isoforms of NRAS, specifically NRAS isoform 2, plays a role in BRAF inhibitor resistance by facilitating alternative survival signaling through the PI3K pathway in the presence of MAPK pathway inhibition. Targeting NRAS isoform 2 may be a beneficial treatment strategy in the prevention and management of BRAF inhibitor resistance in melanoma.